学术治疗性专利应该卖给出价最高的人吗？

Should academic therapeutic patents go to the highest bidder?

机构信息

Universities Allied for Essential Medicines (UAEM), Sarah Lawrence College , 434 E 10th St #4, NY 10009 , USA +1 646 450 0752 ; +1 866 690 1178 ;

出版信息

Expert Opin Ther Pat. 2014 May;24(5):481-4. doi: 10.1517/13543776.2014.904289. Epub 2014 Apr 1.

DOI:10.1517/13543776.2014.904289

PMID:24684243

Abstract

Universities conduct biomedical research with the self-stated goal of disseminating the benefits to the global public. Licensing therapeutic patents to the highest bidder is counterproductive to this aim, as it prioritizes income maximization over dissemination. We believe that licensing strategies focused on promoting broad access to university-discovered therapeutics better serve both the mission of universities and the public good.

摘要

大学进行生物医学研究的自陈目标是将益处传播给全球公众。将治疗性专利许可给出价最高的人是违背这一目标的，因为它优先考虑收入最大化而不是传播。我们认为，专注于促进广泛获得大学发现的治疗方法的许可策略更能服务于大学的使命和公共利益。